Cyclopharm is an established Australian radiopharmaceutical company servicing the global medical community since 1986.
Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of Technegas. Technegas has become the industry gold-standard in diagnostic functional lung imaging technology.
We distribute our products in 57 countries throughout the world with over 1500 nuclear medicine departments utilising Technegas.
2018 represents a significant milestone year for Cyclopharm when our 4 millionth patient will receive a Technegas scan.
Technegas is a structured ultra-fine dispersion of radio-labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,750C. The resultant gaseous substance is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomographic imaging with a nuclear medicine camera for superior functional imaging of the alveolar spaces of the lungs.
Macquarie Medical Imaging
Cyclopharm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging (MMI) represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.
The combination of state-of-the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.